In a woman with a painful palpable retroareolar breast mass and a normal mammogram, what is the appropriate diagnostic and treatment approach?

Ultrasound is the Critical Next Step

Despite the normal mammogram, a painful palpable retroareolar mass requires targeted ultrasound examination to exclude malignancy and characterize the lesion. A normal mammogram does not rule out cancer in the setting of a palpable mass, as mammography has reduced sensitivity in the retroareolar region and can miss 9-14% of cancers that are palpable 1.

Diagnostic Algorithm

Immediate Next Step: Targeted Ultrasound

• Perform ultrasound directly targeted to the palpable retroareolar finding 1
• The combined negative predictive value of mammography plus ultrasound for palpable masses is 97.4-100%, significantly higher than mammography alone 1
• Ultrasound detects 93-100% of cancers that are mammographically occult 1

Critical Principle

Never allow negative imaging to override a clinically suspicious finding 1. The retroareolar location is particularly problematic because:

• Mammography has lower sensitivity in this region compared to other breast areas 2
• 78% of retroareolar carcinomas present as palpable masses 2
• Pain does not exclude malignancy—29 of 37 retroareolar cancers in one series presented with palpable masses 2

Ultrasound Findings Guide Management

If Ultrasound Shows Simple Cyst or Definitively Benign Finding

• Clinical follow-up is appropriate
• No further imaging or biopsy needed 1

If Ultrasound Shows Solid Mass with Benign Features

• Consider image-guided core biopsy given the retroareolar location and symptomatic presentation 1
• While short-interval follow-up may be acceptable for probably benign masses elsewhere (cancer incidence 0-2%), the retroareolar location warrants lower threshold for biopsy 1
• Biopsy is mandatory if the mass is new or enlarging >20% in volume over 6 months 1

If Ultrasound Shows Suspicious Features (BI-RADS 4 or 5)

• Proceed immediately to image-guided core biopsy 1
• Ultrasound-guided core biopsy is preferred over stereotactic when lesion visible on ultrasound (better patient comfort, real-time visualization, no radiation) 1
• Core biopsy is superior to fine-needle aspiration for sensitivity, specificity, and histologic grading 1

If Ultrasound is Negative

• The clinical examination takes precedence 1
• If the mass remains clinically suspicious on physical exam, proceed to biopsy despite negative imaging 1
• Consider MRI only in highly selected cases where clinical suspicion remains high and both mammography and ultrasound are negative, though evidence for this is limited 1

Common Pitfalls to Avoid

1. Do not assume pain equals benign pathology—retroareolar carcinomas frequently present with pain and palpable mass 2

2. Do not rely on mammography alone in the retroareolar region—this area has inherently lower mammographic sensitivity 2

3. Do not delay biopsy if clinical suspicion is high—negative imaging should never override a strongly suspicious physical examination 1

4. Do not use MRI as first-line imaging—there is no established role for MRI in initial evaluation of palpable masses 1

5. Avoid fine-needle aspiration—core biopsy provides superior diagnostic accuracy 1

Age Considerations

While the guidelines emphasize age-based algorithms, the presence of a palpable mass overrides age-based screening recommendations. For women ≥40 years (which applies here given normal mammogram was obtained), the pathway is: mammography → targeted ultrasound → biopsy if indicated 1.